MedPath

efficacy and safety of various aspirin doses in patients with ST-segment myocardial infarction undergoing primary percutaneous coronary interventio

Phase 2
Conditions
ST-segment elevation myocardial infarction (STEMI).
Acute myocardial infarction
Registration Number
IRCT2014122220392N1
Lead Sponsor
Vice chancellor for research, Guilan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
175
Inclusion Criteria

patients with ST-segment myocardial infarction who underwent primary PCI within 12 hours of the onset of heart attack.

Exclusion Criteria

patients with a history of gastrointestinal bleeding and hemorrhagic stroke; opium and alcohol abusers, patients with coagulopathies or history of anticoagulant therapy ; major surgery within 6 weeks; platelets less than 100,000/ microliter; hematocrit less than 25%; creatinine more than 4 mg/dl

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Major adverse cardiovascular outcome. Timepoint: one month and one year after the study. Method of measurement: telephone interview and echcardiogarphy for patients with primary outcome.
Secondary Outcome Measures
NameTimeMethod
Major bleeding. Timepoint: one month and one year after primary PCI. Method of measurement: telephone interview.
© Copyright 2025. All Rights Reserved by MedPath